Loading clinical trials...
Loading clinical trials...
A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
Conditions
Interventions
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Locations
5
United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Cleveland Clinic
Cleveland, Ohio, United States
Regional Infectious Disease Infusion Center
Lima, Ohio, United States
Vanderbilt Center for Human Nutrition
Nashville, Tennessee, United States
Start Date
February 1, 2015
Primary Completion Date
February 1, 2018
Completion Date
February 1, 2018
Last Updated
February 18, 2015
NCT07197944
NCT05561647
NCT06973304
NCT05635747
NCT01990040
NCT05432648
Lead Sponsor
Marathon Pharmaceuticals, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions